RBC Removes 'Speculative Risk' From Apogee Therapeutics, Raises Price Target to $135 From $97 Amid AbbVie Deal, Keeps Sector Perform Rating
Apogee Therapeutics (APGE) has an average rating of overweight and mean price target of $130.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)